Axiom Investors LLC Blueprint Medicines Corp Transaction History

Axiom Investors LLC

$11.2 Billion
Q3 2024

A detailed history of Axiom Investors LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Axiom Investors LLC holds 45,824 shares of BPMC stock, worth $4.15 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

45,824

Previous 49,900 8.17%

Holding current value

$4.15 Million

Previous $5.38 Million 21.23%

% of portfolio

0.04%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$84.1 - $120.5 $342,791 - $491,158	-4,076 Reduced 8.17%	45,824 $4.24 Million
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $479,563 - $612,431	5,630 Added 12.72%	49,900 $5.38 Million
Q1 2024 May 13, 2024	BUY	$73.17 - $99.79 $1.48 Million - $2.02 Million	20,288 Added 84.6%	44,270 $4.2 Million
Q4 2023 Feb 12, 2024	BUY	$43.96 - $92.84 $1.05 Million - $2.23 Million	23,982 New	23,982 $2.21 Million
Q4 2019 Feb 13, 2020	SELL	$66.73 - $82.59 $696,594 - $862,157	-10,439 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$72.9 - $101.41 $720,835 - $1 Million	-9,888 Reduced 48.64%	10,439 $767,000
Q2 2019 Aug 07, 2019	BUY	$73.54 - $97.8 $303,720 - $403,914	4,130 Added 25.5%	20,327 $1.92 Million
Q1 2019 May 13, 2019	SELL	$48.7 - $86.6 $133,194 - $236,850	-2,735 Reduced 14.45%	16,197 $1.3 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $44,157 - $71,957	-969 Reduced 4.87%	18,932 $1.02 Million
Q3 2018 Nov 13, 2018	SELL	$58.91 - $78.32 $89,248 - $118,654	-1,515 Reduced 7.07%	19,901 $1.55 Million
Q2 2018 Aug 13, 2018	BUY	$60.96 - $101.18 $1.31 Million - $2.17 Million	21,416 New	21,416 $1.36 Million

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axiom Investors LLC , based on Form 13F filings with the SEC.

News

Stay updated on Axiom Investors LLC with notifications on news.

Account

Axiom Investors LLC Blueprint Medicines Corp Transaction History